For example, Dotan et al. [22] suggested that among solid organ (kidney, liver, lung, heart) transplant recipients, GLP1-RA use may be linked to significantly lower risk of cardiovascular events, peripheral vascular disease, and mortality. The gene discussed is GLP1R; the disease is vascular disorder.